EPHA2 and cancer: EphA2 expression in cancer cells caused immunosuppression in the TME and therefore conferred resistance to combination immunotherapy through EPHA2/TGF‐β/SMAD axis–dependent activation of prostaglandin‐endoperoxide synthase 2.105